Nasdaq-listed biotechnology firm Sonnet BioTherapeutics has attracted attention by embarking on a new crypto-focused strategy. The company announced its merger with Rorschach I LLC. The resulting entity will operate under the name "Hyperliquid Strategies, Inc." With its treasury of HYPE tokens, it aims to become a strategic player in the crypto world.
$888 million valuation
According to the press release, after the merger, Hyperliquid Strategies will hold 12.6 million HYPE tokens and $305 million in cash reserves. The total value of these assets will be approximately $888 million at closing.
This major merger and transformation is being led by Rorschach I LLC, which is backed by prominent investment firms such as Atlas Merchant Capital LLC and its affiliate Paradigm Operations LP. The new company will continue to be publicly listed on Nasdaq as a crypto treasury management firm but will trade under a new ticker symbol.
Backing from giants like Paradigm, Galaxy, and Pantera
This move is backed by some of the crypto industry's largest investors. Investors such as Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital participated in the merger. Paradigm co-founder Matt Huang said of Hyperliquid:
“Hyperliquid is a well-established crypto project with a strong core team, high-quality product development, and rapid growth. We support this treasury strategy because HYPE tokens are difficult to access in the US. We believe this move will significantly contribute to the Hyperliquid ecosystem in the long term.”
Goal: Accumulate more HYPE
The $305 million in cash in the new structure will be used directly to purchase more HYPE tokens. This will increase Hyperliquid Strategies' token holdings, and the firm is expected to hold one of the largest strategic reserves for HYPE, the native token of the Hyperliquid protocol.
The Hyperliquid protocol generated over $1.5 trillion in perpetual trading volume over the past year. The platform also continued its growth, recently reaching a new high of $11.3 billion in open interest.
With the closing, Atlas Merchant Capital founder and CEO Bob Diamond will become Chairman of Hyperliquid Strategies. Atlas founder and investment director David Schamis will assume the new CEO role. Additionally, former Boston Fed President Eric Rosengren and two independent Sonnet board members will join the new board. Diamond commented on the strategy:
“Partnering with Sonnet to build a robust crypto treasury management strategy is a great opportunity for us. HYPE and the Hyperliquid protocol offer differentiating factors in the crypto asset world. We believe we will maximize these opportunities with our experienced team of investors and operators.”
Sonnet: Transitioning from Biotech to Crypto
Sonnet BioTherapeutics operates as a cancer-focused biologics developer. With this merger, Sonnet will become a subsidiary of Hyperliquid Strategies. The company will continue to focus on its existing biotech projects and will offer shareholders a contingent value right (CVR), which entitles them to receive payments if these projects generate future revenue.
Following the news, Sonnet shares surged significantly on Monday. In pre-market trading, the company's market capitalization surpassed $16 million.
